Skip to main content

Table 3 Base case result

From: Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

 

Total

Cost JPY (USD)

Incremental

Cost JPY (USD)

QALYs

Incremental QALYs

ICER JPY/QALYs

(USD/QALYs)

Reactive

39,809

 

0.6726

  

(365.2)

   

Preemptive

45,109

5300

0.6755

0.0029

1,843,395

(413.8)

(48.6)

(16,912)

  1. JPY: Japanease yen, USD: US dollars, QALYs: Qality adjusted life years
  2. 1 USD = 109.0 JPY (2019 annual exchange rate)